Efficacy and safety of berberine in preventing recurrence of colorectal adenomas: A systematic review and meta-analysis

医学 荟萃分析 结肠镜检查 随机对照试验 梅德林 内科学 科克伦图书馆 黄连 传统医学 中医药 替代医学 结直肠癌 病理 政治学 癌症 法学
作者
Shuangshuang Fang,Song Guo,Shisuo Du,Zhen-Dong Cao,Yang Yang,Su Xiaolan,Wei Wei
出处
期刊:Journal of Ethnopharmacology [Elsevier]
卷期号:282: 114617-114617 被引量:18
标识
DOI:10.1016/j.jep.2021.114617
摘要

Berberine(BBR) is a kind of isoquinoline alkaloids extracted from the rhizomes of Coptis chinensis Franch., which was the main active ingredient. Accumulating evidence has shown that it has potential pharmacological effects in preventing the recurrence of colorectal adenomas.The roles of BBR in the overall recurrence of colorectal adenoma have still not been assessed because of the limitations of the available data and the restriction of a single study. Therefore, we evaluated the effectiveness and safety of BBR in preventing the recurrence of colorectal adenomas through a systematic review and meta-analysis of available data.We searched four English databases (PubMed (MEDLINE), the Cochrane Central Register of Controlled Trials (CENTRAL), Embase and Web of Science) and four Chinese language databases (Chinese Biomedicine (CBM), China National Knowledge Infrastructure (CNKI), Chinese Scientific Journals Database (VIP) and the WanFang Database) from their inception through October 2020. Meta-analysis was performed with RevMan5.3 software after data extraction and the quality of studies assessment.Three randomized controlled clinical trials were included with 1076 patients. Our results illustrated that 1-year and 2-year supplementation with BBR was associated with lower recurrence rate of colorectal adenoma (RR 0.69, 95% CI 0.57 to 0.84, p=0.0001; RR 0.75, 95% CI 0.64 to 0.88, p=0.0004). The relative risk of oral BBR for 1 year and 2 years is not comparable, for 2-year efficacy outcomes were assessed in all participants who had at least one colonoscopy with pathological evaluation after baseline (lots of participants completed the first colonoscopy but discontinued during the second follow-up interval.). Moreover, the results also suggest that BBR had more adverse events than placebo (RR 2.91, 95% CI 1.24 to 6.85, p=0.01). Through the full-text reading, no serious adverse events were observed, and constipation was the most common event which disappears once the drug is discontinued.Generally, the present study indicated that BBR has a comparable therapeutic effect on the prevention of colorectal adenomas recurrence. Adverse reactions are worthy of attention which requires additional studies to obtain a precise conclusion.CRD42020209135.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
酸化土壤改良应助卡布斯采纳,获得10
刚刚
eternal完成签到,获得积分10
1秒前
搜集达人应助PCX采纳,获得10
1秒前
喻文州发布了新的文献求助10
1秒前
认真蚂蚁发布了新的文献求助10
1秒前
ssp发布了新的文献求助10
2秒前
领导范儿应助季秋十二采纳,获得10
3秒前
Cinema发布了新的文献求助10
4秒前
4秒前
科研通AI2S应助纯真的幼丝采纳,获得10
5秒前
5秒前
害羞迎南完成签到,获得积分0
6秒前
Orange应助贪玩的丹蝶采纳,获得10
6秒前
郭郭发布了新的文献求助10
6秒前
开放怀亦完成签到,获得积分10
6秒前
今安完成签到 ,获得积分10
6秒前
7秒前
congcong完成签到 ,获得积分10
7秒前
8秒前
啦啦啦完成签到 ,获得积分10
9秒前
Hello应助中午饭采纳,获得10
9秒前
酷酷的麦片完成签到,获得积分10
10秒前
10秒前
朝花夕拾完成签到,获得积分10
11秒前
盼盼完成签到,获得积分10
12秒前
吴烦恼完成签到,获得积分20
12秒前
12秒前
14秒前
柔弱的树叶完成签到 ,获得积分10
14秒前
多多完成签到 ,获得积分10
14秒前
如意又菡发布了新的文献求助10
16秒前
迷你的以珊完成签到,获得积分10
17秒前
17秒前
20秒前
王贵康发布了新的文献求助30
21秒前
22秒前
22秒前
小一完成签到,获得积分10
22秒前
爱飞的乌龟完成签到,获得积分10
23秒前
24秒前
高分求助中
Manual of Clinical Microbiology, 4 Volume Set (ASM Books) 13th Edition 1000
Sport in der Antike 800
De arte gymnastica. The art of gymnastics 600
Berns Ziesemer - Maos deutscher Topagent: Wie China die Bundesrepublik eroberte 500
Stephen R. Mackinnon - Chen Hansheng: China’s Last Romantic Revolutionary (2023) 500
Sport in der Antike Hardcover – March 1, 2015 500
Boris Pesce - Gli impiegati della Fiat dal 1955 al 1999 un percorso nella memoria 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2421768
求助须知:如何正确求助?哪些是违规求助? 2111410
关于积分的说明 5344630
捐赠科研通 1838909
什么是DOI,文献DOI怎么找? 915439
版权声明 561179
科研通“疑难数据库(出版商)”最低求助积分说明 489564